LINTEX
920106
LINGOOD
833284
NTGEC
870436
4
CG MED EQUIP.
838810
5
Jiayu Holding
300117
US Stock MarketDetailed Quotes
XENE Xenon Pharmaceuticals
- 37.020
- -1.290-3.37%
Close Feb 28 16:00 ET
- 37.020
- 0.0000.00%
Post 20:01 ET
2.83BMarket Cap-12.30P/E (TTM)
37.670High33.270Low1.34MVolume37.000Open38.310Pre Close48.96MTurnover1.89%Turnover RatioLossP/E (Static)76.54MShares47.80052wk High3.75P/B2.62BFloat Cap33.27052wk Low--Dividend TTM70.78MShs Float50.990Historical High--Div YieldTTM11.49%Amplitude2.100Historical Low36.635Avg Price1Lot Size
About Xenon Pharmaceuticals Company
Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.
Company Profile
SymbolXENE
Company NameXenon Pharmaceuticals
Listing DateNov 5, 2014
Issue Price9.00
Founded1996
CEOMr. Ian C. Mortimer
MarketNASDAQ
Employees259
Fiscal Year Ends12-31
Address3650 Gilmore Way,Suite 200
CityBurnaby
ProvinceBritish Columbia
CountryCanada
Zip CodeV5G 4W8
Phone1-604-484-3300
Websitehttp://www.xenon-pharma.com
Company Executives
- Name
- Position
- Salary
- Ian C. Mortimer
- Director, Chief Executive Officer and President
- 9.77M
- Andrea DiFabio
- Chief Legal Officer and Corporate Secretary
- --
- Christopher John Kenney
- Chief Medical Officer
- 3.58M
- Sherry Aulin
- Chief Financial Officer and Principal Accounting Officer
- 3.52M
- James R. Empfield
- Executive Vice President, Drug Discovery
- --
- Dr. Robin Sherrington, PhD
- Executive Vice President, Strategy and Innovation
- 2.37M
- Dawn A. Svoronos
- Chairman of the Board
- 588.37K
- Dr. Elizabeth A. Garofalo, M.D.
- Independent Director
- 548.57K
- Patrick C. Machado, J.D.
- Independent Director
- 559.58K
- Steven Gannon
- Independent Director
- 561.42K
- Dr. Gillian M. Cannon, PhD
- Independent Director
- 770.91K
- Gary Patou, M.D.
- Independent Director
- 560.09K
- Justin David Gover
- Independent Director
- 770.91K
Trending Stocks
Discussing
FOMC leaves rates unchanged, how will you adjust your portfolio?
FOMC left the target Federal Funds rate unchanged at at target of 4.25%-4.5%, how will you adjust your portfolio?
Moo Live
Jan 30 03:25
FOMC Press Conference, January 29, 2025